sábado, 16 de agosto de 2014

Experimental Chikungunya Vaccine Induces Robust Antibody Response

Experimental Chikungunya Vaccine Induces Robust Antibody Response



Experimental Chikungunya Vaccine Induces Robust Antibody Response
A vaccine against chikungunya virus, which is spread by mosquitoes and causes fever and severe joint pain, prompted robust antibody responses in 25 healthy volunteers who participated in a clinical trial conducted by researchers from the National Institute of Allergy and Infectious Diseases (NIAID). Chikungunya virus was first detected in the Americas in late 2013 and number of reported cases has already surged past the half-million mark. More information about the NIAID trial is at:http://www.niaid.nih.gov/news/newsreleases/2014/Pages/ChikungunyaVax.aspx

No hay comentarios:

Publicar un comentario